
Alejandro Gonzalez-Serna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2509454/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Genome-Wide Association Study on Liver Stiffness Changes during Hepatitis C Virus Infection Cure. Diagnostics, 2021, 11, 1501.	2.6	2
2	A genomeâ€wide association study on low susceptibility to hepatitis C virus infection (GEHEP012 study). Liver International, 2019, 39, 1918-1926.	3.9	4
3	Rapid Decrease in Peripheral Blood Mononucleated Cell Telomere Length After HIV Seroconversion, but Not HCV Seroconversion. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, e29-e32.	2.1	20
4	Genotypic susceptibility score (GSS) and CD4+ T cell recovery in HIV-1 patients with suppressed viral load. Journal of Antimicrobial Chemotherapy, 2017, 72, 496-503.	3.0	5
5	Relationship between CCR5(WT/Δ32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection. Clinical Microbiology and Infection, 2017, 23, 318-324.	6.0	5
6	Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens. Journal of Translational Medicine, 2017, 15, 259.	4.4	6
7	Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients. Drug Design, Development and Therapy, 2016, 10, 353.	4.3	2
8	A single untimed plasma drug concentration measurement during low-level HIV viremia predicts virologic failure. Clinical Microbiology and Infection, 2016, 22, 1004.e9-1004.e16.	6.0	21
9	Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure. Antimicrobial Agents and Chemotherapy, 2016, 60, 6398-6401.	3.2	0
10	Performance of HIV-1 Drug Resistance Testing at Low-Level Viremia and Its Ability to Predict Future Virologic Outcomes and Viral Evolution in Treatment-Naive Individuals. Clinical Infectious Diseases, 2014, 58, 1165-1173.	5.8	77
11	HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. Aids, 2014, 28, 1125-1134.	2.2	72
12	Temporal trends in the discontinuation of first-line antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 2202-2209.	3.0	24
13	CD8 TCR β chain repertoire expansions and deletions are related with immunologic markers in HIV-1-infected patients during treatment interruption. Journal of Clinical Virology, 2013, 58, 703-709.	3.1	9
14	"Test-and-Treat―Strategy for Control of HIV and AIDS Can Lead to a Decrease, Not an Increase, of Multidrug-Resistant Viruses. Clinical Infectious Diseases, 2013, 57, 478-479.	5.8	3
15	Correlation of the Virological Response to Short-Term Maraviroc Monotherapy with Standard and Deep-Sequencing-Based Genotypic Tropism Prediction Methods. Antimicrobial Agents and Chemotherapy, 2012, 56, 1202-1207.	3.2	19
16	HIV-1 Tropism Evolution after Short-Term Maraviroc Monotherapy in HIV-1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2012, 56, 3981-3983.	3.2	7
17	Different biological significance of sCD14 and LPS in HIV-infection: Importance of the immunovirology stage and association with HIV-disease progression markers. Journal of Infection, 2012, 65, 431-438.	3.3	41
18	Effect of Maraviroc on HIV Disease Progression-Related Biomarkers. Antimicrobial Agents and Chemotherapy, 2012, 56, 5858-5864.	3.2	19

#	Article	IF	CITATIONS
19	Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment. Antiviral Research, 2012, 95, 207-211.	4.1	6
20	Discordance rates between Trofile® test and short-term virological response to maraviroc. Antiviral Research, 2011, 89, 182-185.	4.1	10
21	Virological Response after Short-Term CCR5 Antagonist Exposure in HIV-Infected Patients: Frequency of Subjects with Virological Response and Associated Factors. Antimicrobial Agents and Chemotherapy, 2011, 55, 4664-4669.	3.2	11
22	Long-Term Immunovirogical Effect and Tolerability of a Maraviroc- Containing Regimen in Routine Clinical Practice. Current HIV Research, 2010, 8, 482-486.	0.5	17
23	TROCAI (Tropism Coreceptor Assay Information): a New Phenotypic Tropism Test and Its Correlation with Trofile Enhanced Sensitivity and Genotypic Approaches. Journal of Clinical Microbiology, 2010, 48, 4453-4458.	3.9	21
24	Correlation between the Trofile(R) test and virological response to a short-term maraviroc exposure in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2009, 64, 845-849.	3.0	28